Trials / Completed
CompletedNCT00824187
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
A Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EE20/DRSP(YAZ, BAY86-5300) | 20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd |
| DRUG | Placebo | Inert tablet |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-01-16
- Last updated
- 2014-04-02
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00824187. Inclusion in this directory is not an endorsement.